Radiotherapy is commonly applied after breast-conserving surgery to reduce the risk of locoregional recurrence of breast cancer and has been shown to be as effective as radical mastectomy ([Fisher *et al*, 2002](#bib21){ref-type="other"}). Although standard radiation therapy is well tolerated by the majority of patients, late normal tissue complications arising from the intrinsic sensitivity of normal tissue, and correlated poor cosmetic results, remain as health concerns of treated breast cancer patients over time ([Cetintas *et al*, 2002](#bib12){ref-type="other"}; [Deutsch and Flickinger, 2003](#bib16){ref-type="other"}; [Smith and Ross, 2004](#bib42){ref-type="other"}). The process of endothelium reconstruction is radiation dose-dependent, progresses over months and years and leads to increases in the severity of both telangiectasia and fibrosis ([Bentzen *et al*, 1989](#bib9){ref-type="other"}; [Archambeau *et al*, 1995](#bib3){ref-type="other"}; [Chen *et al*, 2006](#bib14){ref-type="other"}). Telangiectasias are small dilated blood vessels near the surface of the skin and fibrosis is the development of excess fibrous connective tissue leading to induration. There is, however, considerable inter-individual variability in the development of adverse reactions in normal tissue of irradiated patients. Besides duration, radiation dose and schedule ([Turesson *et al*, 1996](#bib47){ref-type="other"}; [Hill *et al*, 2001](#bib24){ref-type="other"}), patient-related factors, such as age, acute skin reaction and lifestyle factors ([Bentzen and Overgaard, 1991](#bib7){ref-type="other"}; [Bentzen *et al*., 1996](#bib8){ref-type="other"}; [Turesson *et al*, 1996](#bib47){ref-type="other"}; [Johansen *et al*, 2002](#bib27){ref-type="other"}; [Deutsch and Flickinger, 2003](#bib16){ref-type="other"}; [Chen *et al*, 2006](#bib14){ref-type="other"}; [Lilla *et al*, 2007](#bib32){ref-type="other"}), as well as genetic susceptibility ([Bentzen and Overgaard, 1994](#bib6){ref-type="other"}; [Chang-Claude *et al*, 2005](#bib13){ref-type="other"}; [Andreassen *et al*, 2006](#bib2){ref-type="other"}; [Popanda *et al*, 2008](#bib36){ref-type="other"}) have been implicated. Sensitivity to radiation exposure is suggested to be a complex, polygenic trait, which results from the interaction of a number of genes in different cellular pathways ([Travis, 2007](#bib46){ref-type="other"}).

As radiation therapy exerts its cytotoxic effects through damage to cells, proteins and DNA, the individual capacity to repair damaged DNA may modify the response of the normal tissue. Radiation-induced DNA damage is diverse and therefore nearly all DNA repair pathways might be involved in its removal, especially repair of double-strand breaks through mechanisms such as homologous recombination and non-homologous end joining ([Jeggo and Lobrich, 2006](#bib26){ref-type="other"}). In addition, nucleotide and base-excision repair play an important role, mainly in the repair of oxidative DNA damage ([Hoeijmakers, 2001](#bib25){ref-type="other"}).

Furthermore, the complex response to ionising radiation requires the expression and activity of the p53 pathway ([Gudkov and Komarova, 2003](#bib23){ref-type="other"}). The p53 protein is activated through phosphorylation by radiation DNA damage-induced kinases, including ataxia telangiectasia-mutated and the DNA-dependent protein kinase ([Banin *et al*, 1998](#bib5){ref-type="other"}; [Fei and El-Deiry, 2003](#bib20){ref-type="other"}; [Schwartz, 2007](#bib39){ref-type="other"}). Activated p53 protein has various downstream targets, including genes involved in cell-cycle regulation, apoptosis, and DNA repair. Regulation of these processes by p53 controls the cellular response to ionising radiation-induced damage. *p21* is a critical cell-cycle checkpoint gene, regulated tightly by p53. As soon as DNA is damaged by radiation, binding of p53 protein induces transcription of the downstream gene *p21*, which stops cells from entering into the S phase ([Robles *et al*, 2002](#bib38){ref-type="other"}). p21, together with p53, is directly involved in G1/S checkpoint control in response to ionising radiation ([Dotto, 2000](#bib18){ref-type="other"}).

We therefore evaluated the association between several putative functional polymorphisms in six genes involved in DNA repair and two damage response genes and development of late normal tissue complications in a prospective study of breast cancer patients who received radiotherapy after breast-conserving surgery.

Material and methods
====================

Patient population and data collection
--------------------------------------

The methods of this study have been described earlier ([Twardella *et al*, 2003](#bib48){ref-type="other"}; [Chang-Claude *et al*, 2005](#bib13){ref-type="other"}; [Lilla *et al*, 2007](#bib32){ref-type="other"}). Briefly, women diagnosed with breast cancer who received radiotherapy after breast-conserving surgery were enrolled between June 1998 and March 2001 from four radiotherapy units in Germany (Women\'s Clinic at the University of Heidelberg, St Vincentius Clinic in Karlsruhe, City Hospital in Karlsruhe and University Hospital of Mannheim). Patients who received chemotherapy before or during radiation were not eligible for the study. Information on demographic factors, medical history, and lifestyle factors was obtained through self-administered questionnaires. Details on clinical tumor characteristics and treatment regimen were abstracted from patient records. Informed consent was obtained from all participants, and the study was approved by the ethics committee of the University of Heidelberg, the Institutional Review Board for Roswell Park Cancer Institute, and the US Army Medical Research and Materiel Command Human Subjects Research Review Board.

Breast irradiation
------------------

Details on the radiotherapy regimen (total dose, dose per fraction, treatment time, boost dose) were abstracted from the irradiation protocols. As described earlier ([Twardella *et al*, 2003](#bib48){ref-type="other"}), all patients received a common breast irradiation treatment with conformal tangential irradiation with lateral and medial wedge fields, including CT-based planning, simulation, verification, and quality assurance. At three hospitals, the standard regimen included irradiation of the whole breast, either 50 Gy given in 5 × 2.0 Gy fractions or 50.4 Gy in 5 × 1.8 Gy fractions per week, followed by a photon or electron boost with doses ranging from 5 to 20 Gy. Three patients were treated with brachytherapy (20 or 25 Gy). In the fourth radiation department, patients received 56 Gy of whole breast irradiation in 5 × 2.0 Gy fractions without boost. The biologically effective dose (BED) of radiotherapy relative to an irradiation with a fraction dose of 2.0 Gy, that is the normalised total dose (NTD), was calculated to account for differences in fractionation according to the following formula: given the number of fractions *n*, the fraction size of *d*, and an *α/β* ratio of 3 Gy for telangiectasia and 2 Gy for fibrosis.

Follow-up and evaluation of toxicities
--------------------------------------

The occurrence of acute side effects of radiotherapy was monitored and documented by physicians several times during the study. We have earlier reported on acute radiation-induced toxicity, defined as grade 2c and above (at least one moist desquamation or interruption of radiotherapy due to toxicity), in this patient cohort ([Twardella *et al*, 2003](#bib48){ref-type="other"}; [Chang-Claude *et al*, 2005](#bib13){ref-type="other"}; [Ambrosone *et al*, 2006](#bib1){ref-type="other"}; [Popanda *et al*, 2006](#bib37){ref-type="other"}; [Tan *et al*, 2006](#bib44){ref-type="other"}). Patients were recontacted between June 2003 and July 2005 to assess the occurrence of late adverse effects of radiotherapy and course of disease (relapse, metastases, secondary carcinoma, and death). A self-administered questionnaire similar to that applied at baseline was used to collect information on demographic and epidemiological risk factors, and to record behavior changes that may have occurred after radiotherapy. Patients were examined by the study physician or the treating physician to assess the occurrence of late adverse effects of radiotherapy.

The late side effects were classified according to the RTOG/EORTC late radiation morbidity scoring schema ([Seegenschmiedt, 1998](#bib40){ref-type="other"}) supplemented by LENT-SOMA scores. Patients\' general condition, weight changes, nausea and development of lymphatic edema (arm or breast), and adverse reactions of the skin (telangiectasia), subcutaneous tissue (fibrosis) and other organ tissues (heart, lung, larynx) were recorded. The severity of late effects was scored from 0 to 4, whereby the development of side effects of scores ⩾2 was considered to indicate late normal tissue complications.

Genotyping assays
-----------------

Most polymorphisms (see Table 2) were detected by amplification with real-time PCR followed by melting-curve analysis with fluorescence-labeled hybridisation probes in a LightCycler (Roche Diagnostics, Mannheim, Germany) as described earlier ([Chang-Claude *et al*, 2005](#bib13){ref-type="other"}; [Popanda *et al*, 2006](#bib37){ref-type="other"}; [Tan *et al*, 2006](#bib44){ref-type="other"}). The oligonucleotides for analysis of the *XRCC1* -77 polymorphism (rs3213245) were the PCR primers (sense) 5′-ctttagccagcgcaggtcg-3′OH and (antisense) 5′-ccccatgcaggtccctcac-3′OH, sensor 5′-cccgccccctcccactc-3′-FL and anchor 5′-LC Red640-ccctgcccctcggaccccatactc-3′P. The sense primer included a mismatch to avoid stem loops in the amplicon because of the high and repetitive G/C content of the target sequence. PCR primers and probes were designed with the help of Tib Molbiol (Berlin, Germany). Annealing temperature of the primers was 60°C. The PCR was performed for all polymorphisms with Qiagen reagents (Qiagen, Hilden, Germany) in a volume of 10 *μ*l using 10 ng of DNA. Overall, 10% randomly selected samples were analysed by conventional PCR-RFLP to verify the LightCycler results; 100% concordance was found. The insertion of the *TP53* PIN3 polymorphism was identified by standard PCR and electrophoresis ([Tan *et al*, 2006](#bib44){ref-type="other"}). A negative control containing all the reagents but with water instead of the DNA template was included in every amplification set. All genotyping assays were carried out blinded to the clinical diagnosis. For each polymorphism, PCR fragments of the homozygous wild-type allele, the homozygous variant allele, and one heterozygous sample were sequenced.

Statistical analysis
--------------------

Significant differences in distribution of genotypes by presence of late skin toxicities (scores ⩾2) were tested by the *χ*^2^ and Fischer\'s exact tests. Each polymorphism was tested for deviation from Hardy--Weinberg equilibrium by comparing the observed and expected genotype frequencies using the *χ*^2^-test with one degree of freedom. Multivariate unconditional logistic regression analysis was used to assess the association of genotypes with occurrence of late complications of radiotherapy. Odds ratios (OR) and 95% confidence intervals (CI) were computed using the LOGISTIC procedure in SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). Possible effect modification of genotype associations by other covariables was evaluated by the log likelihood ratio test comparing models with and without the first-order interaction terms. All tests were two-sided and considered to be statistically significant with a *P*-value of ⩽0.05. The logistic regression analysis was performed only for the occurrence of telangiectasia, excluding seven patients who developed fibrosis with a score ⩾2 but not telangiectasia. Multivariate models included NTD, age at the time of late toxicity evaluation, and follow-up time since end of radiotherapy. Stepwise backward elimination with *P*⩽0.03 as threshold was used to develop a final model to control for potential confounders. The final model included, in addition hospital facility, acute skin toxicity, a history of hypertension and allergy, skin type (three categories), pack-years of smoking (0, 1--19, ⩾20), and marital status.

Analyses to assess association between haplotypes and risk for telangiectasia were carried out using the function haplo.glm of the R package haplo.stats, which uses a generalised linear model (glm) allowing for an ambiguous linkage phase ([Lake *et al*, 2003](#bib31){ref-type="other"}). The most common haplotype was used as the referent. Possible effect modification of haplotype associations by other covariables were evaluated by the likelihood ratio test. As this was a hypothesis generating study, significance level was defined at *P*\<0.05 although 13 SNPs were tested.

Results
=======

Data on late effects of radiotherapy as well as information on demographic and epidemiological factors were available for 421 breast cancer patients, as reported earlier ([Lilla *et al*, 2007](#bib32){ref-type="other"}; [Kuptsova *et al*, 2008](#bib30){ref-type="other"}). After a median follow-up time of 51 months (range 36--77 months), the most common symptoms of scores ⩾2, which were observed included telangiectasia (32.1%), impairment of the general condition (15.9%), fibrosis (7.1%), lymphatic edema in the arm and breast (6.2%), and pain (5.5%). Of 416 patients (after excluding 3 patients treated with interstitial boost and 2 patients with missing information on fibrosis), 131 patients presented with telangiectasia and 28 with fibrosis of grades ⩾2, whereby 21 patients presented with both adverse reactions. Characteristics of the 409 breast cancer patients who also had genotype data and were included in this analysis (excluding the seven patients presenting with fibrosis only) are shown in [Table 1](#tbl1){ref-type="table"}.

We found a significant association between genetic polymorphisms in the *TP53* gene and risk for telangiectasia ([Table 2](#tbl2){ref-type="table"}). Compared with non-carriers, patients carrying the variant *TP53* 72Pro allele had an increased risk of adverse effects (OR of 1.66, 95% CI: 1.02--2.72). Carriers of the *TP53* PIN3 A2 allele were also at increased risk of telangiectasia (OR 1.95, 95% CI: 1.13--3.35). None of the other genetic polymorphisms studied showed significant associations with occurrence of telangiectasia.

Strong association (linkage disequilibrium) was found between the *TP53* Arg72Pro and *TP53* PIN3 polymorphisms (*P*\<0.001). We therefore investigated haplotype effects of the two *TP53* polymorphisms. Compared with the common ArgA1 haplotype, the ProA2 haplotype containing both variant alleles was associated with a significantly increased OR of 1.97 (95% CI: 1.11--3.52) for telangiectasia ([Table 3](#tbl3){ref-type="table"}). Haplotype association analysis for the *XRCC1* and *XPD* genes with data for at least two genetic polymorphisms did not reveal further significant findings.

Further analysis for effect modification yielded differences in the effect of *TP53* on risk for telangiectasia, according to occurrence of acute skin toxicity (moist desquamation). Thirty women (22.9%) had presented with acute skin toxicity during radiotherapy in patients with telangiectasia, and 45 women (16.2%) in those without telangiectasia. The elevated risk of telangiectasia associated with the *TP53* ProA2 haplotype was found only in patients who did not present with acute toxicity during radiotherapy (OR 2.78, 95% CI: 1.44--5.35) and not in those who experienced acute skin toxicity during radiotherapy (*P*~heterogeneity~=0.06) ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

In this study of breast cancer patients treated with radiotherapy after breast-conserving surgery, we found that variants of *TP53* were associated with an increased risk for developing telangiectasia after radiation therapy. Although both variants, TP53 72Pro and PIN3 A2, were associated with elevated risk, the haplotype results suggested that *cis* effects of the two variants may be most relevant.

Two of the many p53 functions may be important in modulating radiosensitivity. Growth arrest mediated by p53 plays an important role in inhibiting mitotic cell death in epithelia of the small intestine of mice and, thus, is thought to reduce radiation toxicity in these animals ([Komarova *et al*, 2004](#bib29){ref-type="other"}). Also, apoptosis and cell death by mitotic catastrophe have been recognised as an important response to radiation in many cells ([Dewey *et al*, 1995](#bib17){ref-type="other"}; [Weber and Wenz, 2002](#bib49){ref-type="other"}; [Komarova *et al*, 2004](#bib29){ref-type="other"}) as they remove heavily damaged cells from the tissue. Functional analysis of the two *TP53* variants in codon 72 showed that this polymorphism might modulate these two responses. The 72Arg form induced apoptosis more efficiently than the 72Pro form. In contrast, the 72Pro form appeared to induce a higher level of G1 arrest than the 72Arg form giving time to repair ([Thomas *et al*, 1999](#bib45){ref-type="other"}; [Dumont *et al*, 2003](#bib19){ref-type="other"}; [Pim and Banks, 2004](#bib35){ref-type="other"}). Consequently, the 72Pro p53 protein was found to be more efficient in specifically activating p53-dependent DNA repair target genes, and cells carrying the 72Pro allele had significantly higher DNA repair capacity ([Siddique and Sabapathy, 2006](#bib41){ref-type="other"}). Although it is unclear which of the functional differences between the codon 72 polymorphic alleles is more important, our results could be explained by the lower efficiency with which the 72Pro form induced apoptosis of heavily damaged cells after radiation. Repair and reconstitution of the normal tissue function might be incomplete over time in the presence of these cells, leading to late adverse effects which become visible as telangiectasia, a disturbance of the blood vessels.

We also observed an independent effect of the *TP53* PIN3 polymorphism on the risk of late radiation toxicity, but the results of the haplotype analysis suggested the strongest effect on risk conferred by the haplotype containing both variant alleles. The functional significance of *TP53* PIN3 has remained largely unexplored. Our haplotype analysis revealed further that the strongest risk effect of the 72ProA2 haplotype was visible in patients who did not develop severe acute side effects during radiotherapy. We proposed that the Pro allele carriers experienced reduced cell loss by apoptosis and, potentially, mitotic catastrophe during therapy and were, thus, protected from severe acute side effects as we found in our analysis of acute side effects ([Tan *et al*, 2006](#bib44){ref-type="other"}). This protective effect may turn out as a risk factor for late side effects when the irradiated tissue is observed over a longer time. More analyses of the *in vivo* and *in vitro* effects of the *TP53* Arg72Pro and PIN3 polymorphisms are needed, however, before we can apply these *TP53* variants as predictive markers for late side effects of radiotherapy.

p21 plays a direct role in mediating irradiation-induced G1 arrest, with p53 as the transcription factor in this process. This mechanism indicates a possible combined effect of polymorphisms in the two genes. However, p53 may modulate response to radiation damage in the G1 phase of the cell cycle through mechanisms independent of p53-mediated transcriptional activation of p21 and cell-cycle arrest ([Mazzatti *et al*, 2005](#bib33){ref-type="other"}). We did not observe a significant effect of *p21* Ser31Arg polymorphism on the risk of late skin toxicity. Other studies also failed to find an association of this variant with risk or prognosis of breast cancer ([Keshava *et al*, 2002](#bib28){ref-type="other"}; [Azzato *et al*, 2008](#bib4){ref-type="other"}).

In addition, ten polymorphisms causing an amino acid change in six different DNA repair genes were investigated for associations with telangiectasia, but no significant effects were detected. The *XRCC1* Arg399Gln polymorphism has been reported to be associated with telangiectasia but not with fibrosis, particularly in patients who did not receive a boost, albeit based on 167 patients of whom 39 presented with telangiectasia ([Giotopoulos *et al*, 2007](#bib22){ref-type="other"}). This polymorphism was also not found to be associated with severe grade 3 fibrosis after irradiation of the breast ([Andreassen *et al*, 2006](#bib2){ref-type="other"}). A further study, which did not differentiate between early and late adverse reaction to radiotherapy, reported an elevated risk in women carrying both the variant alleles of the Arg194Trp and the Arg399Gln polymorphisms ([Moullan *et al*, 2003](#bib34){ref-type="other"}) and a protective effect for the T-C-G-G haplotype determined by all four *XRCC1* genetic polymorphisms, -77T\>C, Arg194Trp, Arg280His, and Arg399Gln ([Brem *et al*, 2006](#bib11){ref-type="other"}). Although the results appear divergent, the studies differ in the specific type(s) of adverse reactions being studied, the length of follow-up for side effects, and adjustment for patient-related factors; therefore, comparison of the findings is problematic. Polymorphisms in *XRCC3* and *APEX1* were studied in breast cancer patients receiving radiotherapy (summarised in [Chistiakov *et al*, 2008](#bib15){ref-type="other"}; [Popanda *et al*, 2008](#bib36){ref-type="other"}). Consistent with our null results, all of these studies failed to show a contribution of these SNPs to the risk of adverse reactions after radiotherapy, implying that they may not be promising candidates for predicting late radiosensitivity.

To our knowledge, this is the first epidemiological study on the two *TP53* genetic variants as predictors of late tissue reactions to radiation therapy. However, both the *TP53* codon 72 and intron 3 variants have been found to be associated with poorer prognosis of non-small cell lung cancer ([Boldrini *et al*, 2008](#bib10){ref-type="other"}). Patients receiving chemoradiotherapy for advanced head and neck cancer were found to have higher response rates and survival when their tumors expressed the proapoptotic 72 Arg allele ([Sullivan *et al*, 2004](#bib43){ref-type="other"}).

This study has a number of strengths. Breast cancer patients from this cohort were treated similarly, with radiation dosage carefully assessed, and patients were followed prospectively. Improved radiation techniques at the time of patient recruitment, as well as retrieval of individual irradiation dose methods and records, allowed for proper calculations of BED. The phenotype was precisely defined using the standardised scoring system for late toxicity. In addition, we accounted for patient- and treatment-related factors that influenced risk for telangiectasia when assessing the effect of the genetic variants.

Both telangiectasia and subcutaneous fibrosis are among the most common long-term skin side effects of radiation therapy. Owing to differences in physiological response to radiation of the various skin layers involved and thereby possible differing genetic susceptibility, we opted to restrict the present analysis to telangiectasia because of the limited occurrence of fibrosis and therefore restricted power. Progressive nature of these complications, together with longer time to follow-up, may permit later analyses of late normal tissue complications in this cohort in the future.

In conclusion, this prospective study showed that variants in the *TP53* gene are associated with risk of late skin toxicity after accounting for patient-related factors and treatment modalities. As this is the first report on the involvement of p53 in late skin adverse effects, replication of these findings in other studies is encouraged. Advances in the search for biomarkers of radiation-induced late skin side effects may lead to improved treatment choices for breast cancer patients, and improve cosmetic outcome as well as quality of life after surviving breast cancer.

We thank all women who participated in the study; the staff of the participating clinics for their contribution to data collection; and K Smit, S Behrens, and P Waas for excellent technical assistance. This study was supported by the Federal Office for Radiation Protection (projects St Sch. 4116 and 4233), and USAMRMC BCRP DAMD17-02-10500.

###### 

Clinical and demographic characteristics of the breast cancer patients

  **Characteristics**                          **Mean (s.d.)**    **Range**
  ------------------------------------------- ----------------- -------------
  Age late toxicities (years)^a^                 60.6 (8.57)       27--88
  Age radiotherapy (years)^b^                    64.7 (8.59)       31--91
  Total radiation dose (Gy)^c^                   61.8 (4.10)       51--71
  Follow-up time (months)                        51.4 (6.81)       36--77
                                                                       
                                                **Frequency**    **Percent**
  *Body mass index (kg/m^2^)*                                          
   \<25                                              182            44.5
   25--30                                            161            39.4
   \>30                                              66             16.1
                                                                       
  *Tumor stage status*                                                 
   *In situ*                                         36              8.8
   1                                                 277            67.7
   2                                                 92             22.5
   Other or unknown                                   1              0.2
                                                                       
  *Lymph node status*                                                  
   0                                                 314            76.8
   1                                                 57             13.9
   Unknown                                           38              9.3
                                                                       
  *Metastasis status*                                                  
   0                                                 261            63.8
   1                                                  1              0.2
   Unknown                                           147            35.9
                                                                       
  *Boost therapy type*                                                 
   Photon                                            275            67.2
   Electron                                          94             23.0
   No boost                                          40              9.8
                                                                       
  *Radiotherapy clinic*                                                
   University of Heidelberg Women\'s Clinic          228            55.8
   Karlsruhe St Vincentius clinic                    96             23.5
   Karlsruhe City Hospital                           60             14.7
   University Hospital of Mannheim                   25              6.1

Age at the time of late toxicities evaluation.

Age at the end of radiation therapy.

Includes irradiation to the whole breast and boost application.

###### 

Association between polymorphisms in DNA repair and cell-cycle genes and risk of developing late skin toxicity (telangiectasia) with score ⩾2 after radiotherapy

                             **Patients without telangiectasia**   **Patients with telangiectasia**                      
  ------------- ----------- ------------------------------------- ---------------------------------- ----- ------ ------ -------------
  *APEX1*       TT                           71                                  25.9                 39    30.7   1.00         
  Asp148Gln     TG                           134                                 48.9                 65    51.2   1.03   0.58--1.83
  *rs3136820*   GG                           69                                  25.2                 23    18.1   0.66   0.33--1.32
                TG+GG                        203                                 74.1                 88    69.3   0.90   0.53--1.54
                                                                                                                                
  *XRCC1*       TT                           94                                  34.2                 43    33.9   1.00         
  −77 T\>C      TC                           136                                 49.5                 54    42.5   0.97   0.56--1.67
  *rs3213245*   CC                           45                                  16.4                 30    23.6   1.87   0.94--3.70
                TC+CC                        181                                 65.8                 84    66.1   1.17   0.71--1.95
                                                                                                                                
  *XRCC1*       CC                           242                                 88.3                 117   92.1   1.00         
  Arg194Trp     CT                           30                                   11                  10    7.9    0.58   0.24--1.40
  *rs1799782*   TT                            2                                  0.7                   0     0      0          0
                CT+TT                        32                                  11.7                 10     8     0.57   0.24--1.38
                                                                                                                                
  *XRCC1*       GG                           244                                 88.4                 118   92.9   1.00         
  Arg280His     GA                           30                                  10.9                  9    7.1    0.49   0.19--1.24
  *rs25489*     AA                            2                                  0.7                   0     0      0          0
                GA+AA                        32                                  11.6                  9    7.1    0.43   0.17--1.09
                                                                                                                                
  *XRCC1*       GG                           112                                 40.6                 50    39.4   1.00         
  Arg399Gln     GA                           120                                 43.5                 63    49.6   1.09   0.65--1.82
  *rs25487*     AA                           44                                  15.9                 14     11    0.63   0.29--1.37
                GA+AA                        164                                 59.4                 77    60.6   0.96   0.59--1.57
                                                                                                                                
  *XRCC2*       GG                           236                                 85.5                 113    89    1.00         
  Arg188His     GA                           38                                  13.8                 13    10.2   0.83   0.39--1.76
  *rs3218536*   AA                            2                                  0.7                   1    0.8    1.05   0.08--13.93
                GA+AA                        40                                  14.5                 14     11    0.84   0.41--1.74
                                                                                                                                
  *XRCC3*       CC                           104                                  38                  45    35.4   1.00         
  Thr241Met     CT                           126                                  46                  63    49.6   1.05   0.62--1.79
  *rs861539*    TT                           44                                  16.1                 19     15    1.12   0.53--2.40
                CT+TT                        170                                  62                  82    64.6   1.07   0.65--1.77
                                                                                                                                
  *NBS1*        GG                           120                                 43.5                 53    41.7   1.00         
  Glu185Gln     GC                           137                                 49.6                 58    45.7   0.92   0.55--1.54
  *rs1805794*   CC                           19                                  6.9                  16    12.6   2.14   0.88--5.19
                GC+CC                        156                                 56.5                 74    58.3   1.06   0.65--1.72
                                                                                                                                
  *XPD*         GG                           120                                 43.8                 42    33.3   1.00         
  Asp312Asn     GA                           117                                 42.7                 69    54.8   1.51   0.89--2.55
  *rs1799793*   AA                           37                                  13.5                 15    11.9   0.91   0.41--2.01
                GA+AA                        154                                 56.2                 84    66.6   1.36   0.82--2.24
                                                                                                                                
  *XPD*         AA                           109                                 39.6                 42    33.3   1.00         
  Lys751/Gln    AC                           133                                 48.4                 65    51.6   1.15   0.68--1.95
  *rs13181*     CC                           33                                   12                  19    15.1   1.21   0.57--2.58
                AC+CC                        166                                 60.4                 84    66.6   1.16   0.70--1.92
                                                                                                                                
  *P21*         CC                           242                                 87.7                 110   86.6   1.00         
  Ser31Arg      CA                           31                                  11.2                 17    13.4   1.54   0.71--3.32
  *rs1801270*   AA                            3                                  1.1                   0     0      0          0
                CA+AA                        34                                  12.3                 17    13.4   1.27   0.60--2.68
                                                                                                                                
  *TP53*        GG                           160                                 58.0                 64    50.4   1.00         
  Arg72Pro      GC                           96                                  34.8                 49    38.6   1.67   0.98--2.83
  *rs1042522*   CC                           20                                  7.3                  14     11    1.62   0.71--3.70
                GC+CC                        116                                  40                  63    49.6   1.66   1.02--2.71
                                                                                                                                
  *TP53*        A1A1                         214                                 77.6                 87    68.5   1.00         
  PIN3          A1A2                         56                                  20.3                 40    31.5   2.14   1.23--3.71
                A2A2                          6                                  2.2                   0     0      0          0
                A1A2+A2A2                    62                                  22.4                 40    31.5   1.95   1.13--3.37
                                                                                                                                

CI=confidence interval; NTD=normalised total dose; OR=odds ratio.

Adjusted for NTD, age at the time of late toxicities evaluation, time since radiotherapy (months), clinic, acute skin toxicity, high blood pressure, allergy, pack-years (never, \<20, ⩾20), skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/widowed, married/partner).

###### 

Reconstructed haplotypes and the association with risk of developing late skin toxicity (telangiectasia) with score ⩾2 after radiotherapy

  **Gene**                                                   **Haplotype**    **Frequency**  **OR^a^**    **95% CI**
  ---------------------------------------------------------- --------------- --------------- ----------- -------------
  *All patients*                                                                                                
  *TP53*                                                     GA1                  0.71       1                  
                                                             GA2                  0.03       1.02         0.29--3.63
                                                             CA1                  0.16       1.20         0.79--1.82
                                                             CA2^b^               0.11       1.97         1.11--3.52
                                                                                                                
  *Patients without acute toxicity during radiotherapy*^c^                                               
  *TP53*                                                     GA1                  0.71       1                  
                                                             GA2                  0.02       0.68         0.13--3.60
                                                             CA1                  0.16       1.15         0.71--1.85
                                                             CA2                  0.12       2.78         1.44--5.37
                                                                                                                
  *Patients with acute toxicity during radiotherapy*                                                     
  *TP53*                                                     GA1                  0.71       1                  
                                                             GA2                  0.04       1.10         0.09--13.41
                                                             CA1                  0.17       1.47         0.52--4.17
                                                             CA2                  0.09       0.52         0.11--2.53
                                                                                                                
  *All patients*                                                                                                
  *XRCC1*                                                    CCGG                 0.41       1                  
                                                             TCGG                 0.12       1.15         0.66--2.00
                                                             TCGA                 0.36       0.78         0.53--1.15
                                                             TTGG                 0.05       0.51         0.21--1.24
                                                             Rare^d^              0.07       0.56         0.26--1.20
                                                                                                                
  *XPD*                                                      GA                   0.56       1                  
                                                             GC                   0.09       1.25         0.64--2.46
                                                             AA                   0.06       1.14         0.55--2.38
                                                             AC                   0.29       1.09         0.74--1.62

CI=confidence interval; NTD=normalised total dose; OR=odds ratio.

Adjusted for NTD, age the time of late toxicities evaluation, time since radiotherapy (months), clinic, acute skin toxicity, high blood pressure, allergy, pack-years (never, \<20, ⩾20), skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/widowed, married/partner).

A2 allele carries a duplication of 16 bp in intron 3.

*P*=0.06 for effect heterogeneity according to occurrence of acute skin toxicity.

Composed of haplotypes with frequencies below 5%.
